Skip to main content
. 2022 Jan 13;107(9):2108–2120. doi: 10.3324/haematol.2021.279012

Figure 4.

Figure 4.

Progression-free survival per investigator assessment according to TP53 aberration status (del[17p] or TP53 mutation) in the ibrutinib plus obinutuzumab arm. CI: confidence interval; mo: months; NE, not estimable; PFS, progression-free survival.